SG11201912103TA - Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases - Google Patents

Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases

Info

Publication number
SG11201912103TA
SG11201912103TA SG11201912103TA SG11201912103TA SG11201912103TA SG 11201912103T A SG11201912103T A SG 11201912103TA SG 11201912103T A SG11201912103T A SG 11201912103TA SG 11201912103T A SG11201912103T A SG 11201912103TA SG 11201912103T A SG11201912103T A SG 11201912103TA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
amino acids
related diseases
mitochondrial dysfunction
Prior art date
Application number
SG11201912103TA
Other languages
English (en)
Inventor
Paolo Luca Maria Giorgetti
Original Assignee
Professional Dietetics Int S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Professional Dietetics Int S R L filed Critical Professional Dietetics Int S R L
Publication of SG11201912103TA publication Critical patent/SG11201912103TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
SG11201912103TA 2017-07-28 2018-07-20 Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases SG11201912103TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000087359A IT201700087359A1 (it) 2017-07-28 2017-07-28 Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
PCT/IB2018/055425 WO2019021135A1 (en) 2017-07-28 2018-07-20 COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION

Publications (1)

Publication Number Publication Date
SG11201912103TA true SG11201912103TA (en) 2020-01-30

Family

ID=60628070

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912103TA SG11201912103TA (en) 2017-07-28 2018-07-20 Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases

Country Status (22)

Country Link
US (2) US11337946B2 (es)
EP (2) EP3658132B1 (es)
JP (2) JP7266767B2 (es)
KR (3) KR20230117642A (es)
CN (1) CN110996935A (es)
AU (2) AU2018306540B2 (es)
BR (1) BR112020001471A2 (es)
CA (1) CA3070197A1 (es)
CL (1) CL2020000220A1 (es)
DK (1) DK3658132T3 (es)
ES (1) ES2923126T3 (es)
HU (1) HUE059050T2 (es)
IT (1) IT201700087359A1 (es)
LT (1) LT3658132T (es)
MX (2) MX2020001083A (es)
MY (1) MY200975A (es)
PH (1) PH12020500190A1 (es)
PL (1) PL3658132T3 (es)
PT (1) PT3658132T (es)
RS (1) RS63422B1 (es)
SG (1) SG11201912103TA (es)
WO (1) WO2019021135A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087359A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201900002109A1 (it) * 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
JP2021038147A (ja) * 2019-08-30 2021-03-11 国立大学法人 鹿児島大学 ミトコンドリア生合成促進剤
IT202000000454A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
IT202000021664A1 (it) * 2020-09-14 2022-03-14 Iaf Network S P A Formulazione amminoacidica bilanciata
TW202308604A (zh) * 2021-05-10 2023-03-01 國立大學法人東北大學 肌肉量增加用組成物
IT202100029726A1 (it) 2021-11-24 2023-05-24 Professional Dietetics Spa Composizioni oftalmiche per il trattamento di lesioni corneali

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555780T1 (de) * 1997-10-24 2012-05-15 John P Blass Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
ITTO20010580A1 (it) 2001-06-15 2002-12-15 Professional Dietetics Srl Composizioni a base di aminoacidi per il miglioramento della funzioneventricolare miocardica in pazienti affetti da diabete.
ITTO20010804A1 (it) 2001-08-08 2003-02-08 Professional Dietetics Srl Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
US6620850B2 (en) 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
WO2007049818A1 (ja) 2005-10-27 2007-05-03 Ajinomoto Co., Inc. 抗脂肪肝、抗肥満及び抗高脂血症用組成物
US7982066B2 (en) * 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
JP2007161642A (ja) 2005-12-14 2007-06-28 Kyowa Hakko Kogyo Co Ltd アルコール性肝障害抑制剤
KR101919747B1 (ko) 2011-02-17 2018-11-20 각꼬호우진 구루메 다이가쿠 화학요법제의 항종양 활성 증강제
WO2012147901A1 (ja) 2011-04-28 2012-11-01 味の素株式会社 抗癌剤副作用改善用組成物
US20130084378A1 (en) 2011-09-30 2013-04-04 Daesang Corporation Amino acid seasoning compositions comprising l-glutamic acid and l-lysine
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2013188874A1 (en) 2012-06-15 2013-12-19 Gencia Corporation Methods of mitigating side effects of radiation exposure and chemotherapy
CN102772407B (zh) 2012-08-01 2014-09-17 岳茂兴 一种促进神经损伤修复的药物组合物及其应用
US9597367B2 (en) * 2013-04-19 2017-03-21 Bioventures, Llc Methods for improving muscle and heart function
US10226441B2 (en) 2014-12-09 2019-03-12 Nihon Sizen Hakkoh Co., Ltd. Aging inhibitor
MX357998B (es) * 2015-03-20 2018-07-11 Antonio Hernandez Miramontes Jorge Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.
CN107708683A (zh) 2015-05-11 2018-02-16 纽卡斯尔创新有限公司 氨基酸补充
JP6773269B2 (ja) 2015-05-14 2020-10-21 プロフェッショナル ダイエテティクス エス.ピー.エー. 放射線療法および/または化学療法を受けている腫瘍患者における粘膜炎の治療における使用のためのアミノ酸を備える組成物
WO2017020121A1 (en) 2015-07-31 2017-02-09 Val-Chum, Limited Partnership Glycerol-3-phosphate phosphatase activators
RU2741637C2 (ru) 2015-11-27 2021-01-28 Даблгуд Аб Пищевая добавка и композиция для лечения метаболического синдрома
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
EP3691628A1 (en) 2017-10-02 2020-08-12 University of Florida Research Foundation, Incorporated Materials and methods for inhibiting tumor growth
BR112020017142A2 (pt) * 2018-03-05 2020-12-22 Ajinomoto Co., Inc. Composições para melhorar a função cognitiva e um sintoma do tipo ansiedade e para suprimir a atrofia cerebral.
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
US20220394508A1 (en) 2019-11-11 2022-12-08 Lg Electronics Inc. Vehicular distributed antenna system operating in wireless communication system and method for operating same
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
IT202000000454A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
WO2022266480A1 (en) 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof

Also Published As

Publication number Publication date
KR20240063205A (ko) 2024-05-09
WO2019021135A1 (en) 2019-01-31
KR20200033872A (ko) 2020-03-30
RU2019141152A3 (es) 2021-09-10
AU2018306540B2 (en) 2023-11-30
AU2018306540A1 (en) 2020-02-20
PH12020500190A1 (en) 2020-09-28
ES2923126T3 (es) 2022-09-23
HUE059050T2 (hu) 2022-10-28
PT3658132T (pt) 2022-07-08
MX2022010774A (es) 2023-02-23
CN110996935A (zh) 2020-04-10
IT201700087359A1 (it) 2019-01-28
EP3658132B1 (en) 2022-04-13
CL2020000220A1 (es) 2020-07-31
CA3070197A1 (en) 2019-01-31
MY200975A (en) 2024-01-27
US20220249418A1 (en) 2022-08-11
AU2023266256A1 (en) 2023-12-07
RU2770660C2 (ru) 2022-04-20
RS63422B1 (sr) 2022-08-31
JP7513311B2 (ja) 2024-07-09
RU2019141152A (ru) 2021-08-30
JP2020528400A (ja) 2020-09-24
JP7266767B2 (ja) 2023-05-01
KR20230117642A (ko) 2023-08-08
DK3658132T3 (da) 2022-07-04
BR112020001471A2 (pt) 2020-09-15
US11337946B2 (en) 2022-05-24
KR102566297B1 (ko) 2023-08-10
MX2020001083A (es) 2022-08-31
EP3658132A1 (en) 2020-06-03
JP2023071939A (ja) 2023-05-23
US20200230093A1 (en) 2020-07-23
EP3915553A1 (en) 2021-12-01
LT3658132T (lt) 2022-07-25
US11957651B2 (en) 2024-04-16
PL3658132T3 (pl) 2022-08-01

Similar Documents

Publication Publication Date Title
SG11201912103TA (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases
IL284371B (en) Amino acid compounds and methods for treating liver diseases
IL256085B (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
IL253195B (en) Pharmaceutical preparations containing synthetic glycans for use in the treatment of diseases of the digestive system and methods and methods for their preparation
IL273959A (en) Methods and preparations for the treatment of rare diseases
EP3337465A4 (en) Compositions and methods of use in combination for the treatment and diagnosis of autoimmune diseases
IL272336A (en) Amino acid compounds for the treatment of nerve damage
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3185862A4 (en) PROTECTIVE METALOTHION ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES
ZA202007834B (en) Compositions comprising amino acids for use in the prevention and treatment of liver diseases
SG11201912098SA (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases
PL3294279T3 (pl) Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
PL3515409T3 (pl) Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych
EP3265108A4 (en) PEPTIDES AND COMPOSITIONS AS WELL AS USES THEREOF IN THE TREATMENT OF DISEASES
PL3006027T3 (pl) Kompozycje zawierające aminokwasy do stosowania w leczeniu ogólnoustrojowego stanu zapalnego związanego z udarem u pacjentów z dysfagią
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201817346D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
IL243402A0 (en) Methods for identifying preparations for use in the treatment of heart diseases and the use of preparations for the treatment of these diseases